Grants and Contributions:
Title:
The characterization of novel HDAC6 inhibitors and assessment of therapeutic impact
Agreement Number:
1028318
Agreement Value:
$75,000.00
Agreement Date:
Mar 1, 2025 - Mar 27, 2026
Description:
The characterization of novel HDAC6 inhibitors and assessment of therapeutic impact.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5H 2R2
Reference Number:
172-2024-2025-Q4-1028318
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
783573306
Recipient Type:
For-profit organization
Recipient's Legal Name:
HDAX Therapeutics Inc.
Federal Riding Name:
Toronto Centre
Federal Riding Number:
35108
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710